Could community pharmacies play a greater role in infectious disease care?
Clinical pharmacist Kate Mackie discusses the expanding role of community pharmacies in managing infectious diseases like HIV and hepatitis C. The shift includes administering long-acting injectable therapies and conducting point-of-care testing.
Why it matters
Expanding pharmacy services can improve patient access to specialized care and reduce the burden on traditional clinical settings.
Emerging models are focusing on HIV, viral hepatitis and STI care in community pharmacy settings.
From long-acting injectable HIV therapies to hepatitis C testing, new models of care are creating opportunities for pharmacists to expand their impact. Few understand that shift better than the Burnet Institute’s Kate Mackie, an infectious diseases clinical pharmacist with more than 20 years’ experience across HIV, viral hepatitis and sexual health.
Ahead of her PSA26 Masterclass , co-delivered with Monash University infectious diseases Professor Joseph Doyle and Associate Professor Amanda Wade, Ms Mackie shares some of the trends shaping the future of care and what pharmacists need to know to stay ahead.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in